4.7 Review

Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus

出版社

ELSEVIER
DOI: 10.1016/j.bbadis.2021.166148

关键词

Type 2 diabetes mellitus; Cardiovascular risk; Oxidative stress; Inflammation; Glycation; Novel biomarkers

资金

  1. Eli Lilly
  2. MSD
  3. Novo Nordisk
  4. Novartis
  5. Sanofi-Aventis
  6. AstraZeneca
  7. Boehringer Ingelheim
  8. Coca-Cola
  9. Medtronic
  10. Merck
  11. Roche Diagnostics
  12. Sanofi
  13. TrigoCare International
  14. Pfizer
  15. Amgen
  16. Kowa
  17. Meda
  18. Mylan
  19. Merck Sharp Dohme
  20. Servier

向作者/读者索取更多资源

Diabetes is a major risk factor for cardiovascular disease, with high blood glucose leading to increased reactive oxygen species and affecting endothelial function and atherosclerotic plaque formation. Biomarkers play a crucial role in screening, prediction, diagnosis, and monitoring of cardiovascular risks associated with diabetes.
Diabetes represents the leading risk factor for the development of cardiovascular disease (CVD). Chronic hyperglycemia and/or acute post-prandial changes in blood glucose determine an increase in reactive oxygen species (ROS), which play a fundamental role in endothelial dysfunction and in the nuclear transport of proatherogenic transcription factors that activate the inflammasome. In addition, the glycemic alteration favors the formation and stabilization of atherosclerotic plaque through the mechanism of non-enzymatic glycation of different molecules, with the establishment of the so-called advanced glycosylation end products (AGE). Laboratory information provided by the level of biomarkers could make a quantitative and qualitative contribution to the clinical process of screening, prediction, prevention, diagnosis, prognosis and monitoring of cardiovascular (CV) risk linked to diabetes. This review describes the importance of specific biomarkers, with particular focus on novel ones, for stratifying and management of diabetes CV risk.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据